Cytokinetics Inc
Cytokinetics Inc is a late-stage biopharmaceutical company focused on improving cardiac contractility and reducing cardiac fatigue
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cytokinetics' stock with a target price of $81.69, indicating strong potential growth.
Financial Health
Cytokinetics is generating solid revenue and cash flow, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CYTK
Cardio-Metabolic Drugs: Beyond Weight Loss Benefits
Following new data showing Novo Nordisk's Wegovy has superior cardiovascular benefits over a key rival, the competitive landscape for weight-loss drugs has intensified. This theme focuses on the pharmaceutical giants battling for dominance and the innovative biotechs whose research in related metabolic and cardiovascular fields is now more valuable than ever.
Published: September 1, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory milestones can materially move the share price, though outcomes are binary and performance can vary.
Partner Collaborations
Deals with larger pharmas can provide funding and commercial reach, but may mean shared revenue and less autonomy.
Science Focus
Targeting muscle contractility is a differentiated scientific approach with broad potential, yet scientific and regulatory hurdles remain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
